MAM
Mipim names Nicolas Boffi as new director
PARIS: Rx France has appointed Nicolas Boffi as director of Mipim, the global urban festival that each March draws more than 20,000 delegates to Cannes. An engineer and urban planner by training, Boffi has over two decades of experience in real estate and urban development, spanning project management, business development and public affairs.
He joins from Arcadis, where he led strategy for the global cities programme as Paris city executive, working with both the private sector and city leaders on sustainable projects in the French capital and beyond.
Boffi succeeds Nicolas Kozubek, who steered Mipim through a turbulent period of industry change. Under his watch, Mipim became a forum where real-estate players and policymakers confronted geopolitical risk, technological disruption and the shift towards sustainability.
Filippo Rean, managing director at Rx France, said Boffi’s “strategic mindset and track record in aligning public and private priorities” would help sharpen Mipim’s position as the place where cities’ biggest challenges—sustainability, resilience and competitiveness—are tackled head-on.
Boffi said his priority was to deepen dialogue between the public and private sectors. “The next few years will bring economic, political and fiscal challenges that demand collaboration and bold decision-making,” he said. “Mipim must be where uncertainty turns into opportunity.”
Expect new content under his leadership, from a sharper focus on AI disruption to the race to net zero.
Mipim returns to the Palais des Festivals in Cannes from 9-13 March 2026. The Mipim Asia Summit runs on 3-4 December 2025 in Hong Kong.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
